CPSE:ALK BPharmaceuticals
ALK-Abelló (CPSE:ALK B) Lifted Guidance And Won NICE Backing, Is It Cheap?
ALK-Abelló (CPSE:ALK B) is in focus after reporting higher year on year sales and net income for the second quarter of 2026, slightly raising full year revenue guidance, and securing new NICE recommendations in the UK.
At a share price of DKK210.2, ALK-Abelló has seen the 90 day share price return fall 20.74% and the 30 day share price return decline 6.83%. This is the case even though the 1 year total shareholder return is 6.22% and the 3 year total shareholder return is about 2.6x,...